LT3043803T - Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas - Google Patents
Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimasInfo
- Publication number
- LT3043803T LT3043803T LTEPPCT/US2014/054930T LT14054930T LT3043803T LT 3043803 T LT3043803 T LT 3043803T LT 14054930 T LT14054930 T LT 14054930T LT 3043803 T LT3043803 T LT 3043803T
- Authority
- LT
- Lithuania
- Prior art keywords
- nucleotide
- nucleoside compositions
- nucleoside
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361876473P | 2013-09-11 | 2013-09-11 | |
US201461923317P | 2014-01-03 | 2014-01-03 | |
US201461986577P | 2014-04-30 | 2014-04-30 | |
PCT/US2014/054930 WO2015038596A1 (en) | 2013-09-11 | 2014-09-10 | Nucleotide and nucleoside compositions and uses related thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3043803T true LT3043803T (lt) | 2022-08-10 |
Family
ID=52666219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2014/054930T LT3043803T (lt) | 2013-09-11 | 2014-09-10 | Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas |
Country Status (12)
Country | Link |
---|---|
US (4) | US10149859B2 (lt) |
EP (2) | EP3043803B1 (lt) |
JP (3) | JP6762873B2 (lt) |
DK (1) | DK3043803T3 (lt) |
ES (1) | ES2927955T3 (lt) |
HR (1) | HRP20220911T1 (lt) |
LT (1) | LT3043803T (lt) |
PL (1) | PL3043803T3 (lt) |
SI (1) | SI3043803T1 (lt) |
TW (1) | TW201542581A (lt) |
UY (1) | UY35732A (lt) |
WO (1) | WO2015038596A1 (lt) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9422323B2 (en) | 2012-05-25 | 2016-08-23 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
IN2015DN04090A (lt) | 2012-11-16 | 2015-10-09 | Univ Cardiff | |
ES2927955T3 (es) * | 2013-09-11 | 2022-11-14 | Univ Emory | Composiciones de nucleótidos y nucleósidos y sus usos |
DK3160476T3 (da) | 2014-06-24 | 2020-12-21 | Janssen Biopharma Inc | Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner |
US9603863B2 (en) * | 2014-06-24 | 2017-03-28 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
KR102407935B1 (ko) | 2014-06-25 | 2022-06-10 | 뉴카나 피엘씨 | 젬시타빈 전구 약물 |
RS59264B1 (sr) * | 2014-11-28 | 2019-10-31 | NuCana plc | Novi 2’ i/ili 5’ derivati 3’-deoksi adenozina supstituisani aminokiselinskim estrom fosforamidata, kao antikancerska jedinjenja |
EP3233878A4 (en) | 2014-12-15 | 2019-02-20 | Emory University | PHOSPHORAMIDATE FOR THE TREATMENT OF HEPATITIS C VIRUS |
KR20230130175A (ko) | 2014-12-26 | 2023-09-11 | 에모리 유니버시티 | N4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도 |
GEP20237502B (en) | 2015-03-06 | 2023-04-25 | Atea Pharmaceuticals Inc | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
CN108350016B (zh) | 2015-09-02 | 2021-07-27 | 艾伯维公司 | 抗病毒四氢呋喃衍生物 |
CN106674297A (zh) * | 2015-11-11 | 2017-05-17 | 中国科学院生态环境研究中心 | 具有抗癌活性的新型krn7000类似物及合成方法 |
US20190085013A1 (en) * | 2016-03-07 | 2019-03-21 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
MX2019002430A (es) | 2016-08-31 | 2019-07-04 | Fujifilm Corp | Agente antitumoral, mejorador del efecto antitumoral, y kit antitumoral. |
CN116036114A (zh) | 2016-09-07 | 2023-05-02 | 阿堤亚制药公司 | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 |
WO2018110678A1 (ja) * | 2016-12-16 | 2018-06-21 | 国立大学法人岐阜大学 | ヌクレオシド誘導体及びその利用 |
CN115477679A (zh) | 2017-02-01 | 2022-12-16 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
US10688112B2 (en) | 2017-07-13 | 2020-06-23 | Emory University | Lipid disulfide prodrugs and uses related thereto |
US11780874B2 (en) | 2017-10-31 | 2023-10-10 | Yamasa Corporation | Nucleoside derivative and use thereof |
GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
BR122022008466B1 (pt) | 2017-12-07 | 2023-12-05 | Emory University | Uso de um composto |
EP3732180A4 (en) * | 2017-12-27 | 2022-05-11 | Emory University | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID CELL SPECIFIC ANTIVIRAL AGENTS |
JP7266896B2 (ja) * | 2018-03-09 | 2023-05-01 | 国立研究開発法人科学技術振興機構 | β修飾リン酸化合物前駆体、β修飾リン酸化合物、反応阻害剤及びこれを含む医薬並びに反応阻害方法 |
KR20200140865A (ko) | 2018-04-10 | 2020-12-16 | 아테아 파마슈티컬즈, 인크. | 간경변증을 갖는 hcv 감염 환자의 치료 |
CN110655546B (zh) * | 2018-12-18 | 2023-05-16 | 安徽贝克制药股份有限公司 | 索非布韦衍生物及其制备方法和应用 |
CN109503688A (zh) * | 2018-12-21 | 2019-03-22 | 佛山科学技术学院 | 具有抑制病毒复制活性的核苷磷酸长链酯类似物、制备方法及其药物用途 |
JP7233660B2 (ja) * | 2019-04-05 | 2023-03-07 | 株式会社日本触媒 | 架橋型人工ヌクレオシドの製造 |
CN110105416B (zh) * | 2019-06-17 | 2022-07-12 | 大连大学 | 一种4-S-5-Br-2’,3’,5’-O-三乙酰基尿苷合成方法 |
CN110204584B (zh) * | 2019-06-17 | 2022-09-09 | 大连大学 | 一种4-s-2’,3’,5’-o-三乙酰基尿苷合成方法 |
JOP20220130A1 (ar) | 2019-12-06 | 2023-01-30 | Vertex Pharma | مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم |
US12030903B2 (en) | 2020-02-18 | 2024-07-09 | Gilead Sciences, Inc. | Antiviral compounds |
TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
KR102145197B1 (ko) * | 2020-03-10 | 2020-08-18 | 부광약품 주식회사 | 코로나바이러스를 치료하기 위한 l-뉴클레오사이드의 용도 |
EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2022081823A1 (en) * | 2020-10-14 | 2022-04-21 | Temple University -Of The Commonwealth System Of Higher Education | Pharmacologic approach for suppression of coronaviruses |
CN112778356B (zh) * | 2020-12-26 | 2022-07-01 | 山东日兴新材料股份有限公司 | 一种三(三溴新戊基)磷酸酯阻燃剂的一锅法合成工艺 |
CN112661802B (zh) * | 2021-01-25 | 2022-05-13 | 阿里生物新材料(常州)有限公司 | 一种3′-甲氧基鸟苷的合成方法 |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
JP2024512771A (ja) | 2021-04-16 | 2024-03-19 | ギリアード サイエンシーズ, インコーポレイテッド | アミドを使用してカルバヌクレオシドを調製する方法 |
CN112979733B (zh) * | 2021-04-25 | 2021-09-10 | 南京颐媛生物医学研究院有限公司 | 抗乙肝病毒的化合物及其制备方法和应用 |
EP4333859A1 (en) * | 2021-05-05 | 2024-03-13 | Emory University | Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto |
IL308953A (en) | 2021-06-04 | 2024-01-01 | Vertex Pharma | N-Hydroalkyl(Hetero)Aryl)Tetrahydrofuran Carboxamides as Natrene Channel Modulators |
CN113278041B (zh) * | 2021-07-16 | 2021-10-19 | 南京颐媛生物医学研究院有限公司 | 一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用 |
CN113501853B (zh) * | 2021-09-13 | 2021-12-07 | 南京颐媛生物医学研究院有限公司 | 4-硫代尿嘧啶脱氧核苷磷酸酯及其抗病毒药物用途 |
CN113735927B (zh) * | 2021-10-18 | 2024-06-28 | 厦门蔚扬药业有限公司 | 一种核苷酸类似物及其制备方法和用途 |
WO2023086557A1 (en) * | 2021-11-11 | 2023-05-19 | Emory University | Nucleosides for the treatment of dna virus infections |
US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
CN116554249A (zh) * | 2022-01-28 | 2023-08-08 | 北京恩泰伟医药科技有限公司 | 抗病毒化合物及其用途 |
WO2023178228A1 (en) * | 2022-03-16 | 2023-09-21 | Pharmalectin, Inc. | Lectin-binding carbohydrates for treating viral infections |
EP4248949A1 (en) | 2022-03-21 | 2023-09-27 | R.G.C.C. Holdings AG | Liposomal compositions |
WO2024137577A1 (en) * | 2022-12-19 | 2024-06-27 | Ohio State Innovation Foundation | Multiparametric integrated molecular detection of viral antigens and viral nucleic acids |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3404144A (en) * | 1965-12-23 | 1968-10-01 | Research Corp | 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds |
DE2041735A1 (de) * | 1970-08-22 | 1972-02-24 | Merck Patent Gmbh | Thio-pyrimidin-derivate |
US3975374A (en) * | 1970-12-21 | 1976-08-17 | The Upjohn Company | Process for preparing 2-thiouracil nucleosides |
JPS4947379A (lt) * | 1972-09-12 | 1974-05-08 | ||
PL107865B1 (pl) | 1977-04-27 | 1980-03-31 | Polska Akademia Nauk Instytut | Method of obtaining styrene oxide sposob otrzymywania tlenku styrenu |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US4954485A (en) * | 1987-10-20 | 1990-09-04 | Sanyo-Kokusaku Pulp Co., Ltd. | 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them |
IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
ES2276404T3 (es) | 1995-06-07 | 2007-06-16 | Emory University | Nucleosidos con actividad antivirus de la hepatitis-b. |
US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
JPH107694A (ja) * | 1996-06-21 | 1998-01-13 | Toagosei Co Ltd | 3’−アミノ−2−チオピリミジンヌクレオシド |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
WO1999041266A1 (en) | 1998-02-12 | 1999-08-19 | Emory University | Sphingolipid derivatives and their methods of use |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6461422B1 (en) * | 2000-01-27 | 2002-10-08 | Chartpak, Inc. | Pressure sensitive ink jet media for digital printing |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN101099745A (zh) * | 2000-05-26 | 2008-01-09 | 艾登尼科斯(开曼)有限公司 | 处理黄病毒和瘟病毒的方法和组合物 |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
CN1482914A (zh) | 2000-12-26 | 2004-03-17 | 三菱制药株式会社 | 丙型肝炎治疗剂 |
JP2005504087A (ja) * | 2001-09-28 | 2005-02-10 | イデニクス(ケイマン)リミテツド | 4’が修飾されたヌクレオシドを使用するc型肝炎ウイルス治療のための方法および組成物 |
JP2005536440A (ja) * | 2001-09-28 | 2005-12-02 | イデニクス(ケイマン)リミテツド | 4’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物 |
PL197669B1 (pl) * | 2002-02-28 | 2008-04-30 | Pan Inst Biochemii I Biofizyki | Nowe analogi 2',3'-dideoksy-3'-fluorotymidyny o aktywności przeciwko wirusom (54) ludzkiego niedoboru immunologicznego HIV-1 i HIV-2, sposób ich wytwarzania oraz zawierające je środki farmaceutyczne |
RU2004135392A (ru) | 2002-05-06 | 2005-06-27 | Дженелэбс Текнолоджиз, Инк. (Us) | Производные нуклеозидов для лечения инфекции, вызываемой вирусом гепатита с |
TW200500375A (en) | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
US20040035547A1 (en) | 2002-08-20 | 2004-02-26 | 3M Innovative Properties Company | Metal matrix composites, and methods for making the same |
US7902203B2 (en) | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
WO2006121820A1 (en) * | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
JP2009521479A (ja) | 2005-12-21 | 2009-06-04 | アボット・ラボラトリーズ | 抗ウイルス化合物 |
HUP0600042A3 (en) * | 2006-01-19 | 2012-12-28 | Debreceni Egyetem | New medical use of thiolated pyrimidine-mononucleotides and -nucleosides |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
ES2453591T3 (es) | 2007-09-17 | 2014-04-08 | Abbvie Bahamas Ltd. | Derivado de uracilo o timina para el tratamiento de la hepatitis C |
MX2010002904A (es) | 2007-09-17 | 2010-06-02 | Abbott Lab | N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
WO2010111437A1 (en) | 2009-03-25 | 2010-09-30 | Abbott Laboratories | Antiviral compounds and uses thereof |
SG10201400957UA (en) | 2009-03-25 | 2014-09-26 | Abbott Lab | Antiviral Compounds And Uses Thereof |
JP5734956B2 (ja) | 2009-04-15 | 2015-06-17 | アッヴィ・インコーポレイテッド | 抗ウィルス化合物 |
UY32699A (es) | 2009-06-11 | 2010-12-31 | Abbott Lab | Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
PE20130198A1 (es) | 2010-03-10 | 2013-03-24 | Abbvie Bahamas Ltd | Composiciones solidas |
US8691775B2 (en) * | 2010-04-19 | 2014-04-08 | Back Bay Scientific, Llc | Use of drugs that activate P2Y receptors to enhance synaptogenesis |
US8748374B2 (en) | 2010-06-07 | 2014-06-10 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
CA2805748A1 (en) | 2010-07-16 | 2012-01-19 | Shashank Shekhar | Process for preparing n-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide |
US8871737B2 (en) | 2010-09-22 | 2014-10-28 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
TWI451439B (zh) | 2010-12-10 | 2014-09-01 | Phison Electronics Corp | 記憶體儲存裝置、其記憶體控制器與資料寫入方法 |
MX2013006828A (es) | 2010-12-16 | 2014-10-14 | Abbvie Inc | Compuestos antivirales. |
CN103354808B (zh) | 2010-12-16 | 2016-08-10 | Abbvie公司 | 抗病毒化合物 |
CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
PE20140039A1 (es) | 2010-12-30 | 2014-03-01 | Enanta Pharm Inc | Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina |
EP3384938A1 (en) | 2011-09-12 | 2018-10-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
ES2927955T3 (es) * | 2013-09-11 | 2022-11-14 | Univ Emory | Composiciones de nucleótidos y nucleósidos y sus usos |
EP3233878A4 (en) * | 2014-12-15 | 2019-02-20 | Emory University | PHOSPHORAMIDATE FOR THE TREATMENT OF HEPATITIS C VIRUS |
-
2014
- 2014-09-10 ES ES14844012T patent/ES2927955T3/es active Active
- 2014-09-10 JP JP2016542060A patent/JP6762873B2/ja active Active
- 2014-09-10 HR HRP20220911TT patent/HRP20220911T1/hr unknown
- 2014-09-10 EP EP14844012.6A patent/EP3043803B1/en active Active
- 2014-09-10 DK DK14844012.6T patent/DK3043803T3/da active
- 2014-09-10 US US14/917,681 patent/US10149859B2/en active Active
- 2014-09-10 TW TW103131136A patent/TW201542581A/zh unknown
- 2014-09-10 EP EP22170131.1A patent/EP4094767A1/en active Pending
- 2014-09-10 LT LTEPPCT/US2014/054930T patent/LT3043803T/lt unknown
- 2014-09-10 WO PCT/US2014/054930 patent/WO2015038596A1/en active Application Filing
- 2014-09-10 PL PL14844012.6T patent/PL3043803T3/pl unknown
- 2014-09-10 SI SI201431976T patent/SI3043803T1/sl unknown
- 2014-09-11 UY UY0001035732A patent/UY35732A/es active IP Right Grant
-
2018
- 2018-11-21 US US16/198,240 patent/US11166973B2/en active Active
-
2020
- 2020-04-24 JP JP2020077187A patent/JP7045411B2/ja active Active
-
2021
- 2021-10-27 US US17/512,014 patent/US11857560B2/en active Active
-
2022
- 2022-03-17 JP JP2022042207A patent/JP7508501B2/ja active Active
-
2023
- 2023-11-21 US US18/515,989 patent/US20240173345A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3043803B1 (en) | 2022-04-27 |
DK3043803T3 (da) | 2022-08-01 |
JP2022081641A (ja) | 2022-05-31 |
US11857560B2 (en) | 2024-01-02 |
US20160220595A1 (en) | 2016-08-04 |
JP7508501B2 (ja) | 2024-07-01 |
SI3043803T1 (sl) | 2022-09-30 |
JP6762873B2 (ja) | 2020-09-30 |
JP2020143073A (ja) | 2020-09-10 |
HRP20220911T1 (hr) | 2022-10-28 |
EP4094767A1 (en) | 2022-11-30 |
US20190298750A1 (en) | 2019-10-03 |
UY35732A (es) | 2015-06-30 |
US11166973B2 (en) | 2021-11-09 |
PL3043803T3 (pl) | 2022-11-07 |
JP7045411B2 (ja) | 2022-03-31 |
ES2927955T3 (es) | 2022-11-14 |
JP2016530313A (ja) | 2016-09-29 |
EP3043803A1 (en) | 2016-07-20 |
EP3043803A4 (en) | 2017-03-29 |
US10149859B2 (en) | 2018-12-11 |
US20220296626A1 (en) | 2022-09-22 |
WO2015038596A1 (en) | 2015-03-19 |
US20240173345A1 (en) | 2024-05-30 |
TW201542581A (zh) | 2015-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269461B (en) | Cytidine-5-carboxamide modified nucleotide preparations and related methods | |
SI3043803T1 (sl) | Nukleotidne in nukleozidne sestave in njihova uporaba | |
HK1220463A1 (zh) | 修飾的核苷或核苷酸 | |
HK1224229A1 (zh) | 取代的核苷,核苷酸及其類似物 | |
HK1222178A1 (zh) | 取代的核苷、核苷酸及其類似物 | |
IL245014B (en) | Nucleosides, modified nucleotides and their analogs | |
HK1215595A1 (zh) | 白細胞介素- 藥物組合物和使用方法 | |
HK1210619A1 (en) | Novel nucleoside phosphoramidate compound and use thereof | |
GB201313235D0 (en) | Antiviral Compositions Methods and Animals | |
EP2953474A4 (en) | COMPOSITIONS AND METHODS | |
GB201313423D0 (en) | Compositions and methods | |
GB201308072D0 (en) | Compositions and methods | |
EP2957567A4 (en) | NUCLEOSIDE AND NUCLEOTIDE WITH AN NITROGENIC HETEROCYCLIC STRUCTURE | |
EP2928876A4 (en) | NUCLEOSID KINASEBYPASS COMPOSITIONS AND METHOD | |
HK1220388A1 (zh) | 尿苷核苷衍生物、組合物及使用方法 | |
GB201321693D0 (en) | Composition and uses thereof | |
IL276126B (en) | Preparations containing l-4-chloroquinonerine and their uses | |
GB201305813D0 (en) | Compositions and methods | |
EP2964610A4 (en) | VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF | |
IL233475A0 (en) | Carbocyclic nucleosides, preparations containing them and their uses | |
ZA201500493B (en) | Glycoconjugation processes and compositions | |
GB201308242D0 (en) | Compositions and uses thereof | |
GB201312393D0 (en) | Compositions and Methods | |
GB201301022D0 (en) | Composition and uses thereof |